2023-506352-24-00招募中3 期
BMS CV027-031, A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 282
- 试验地点
- 78
- 主要终点
- Change from baseline in KCCQ CSS at Week 48
研究概览
简要总结
- To assess the efficacy of a 48-week course of mavacamten compared to placebo on patient reported health status (symptoms and physical limitations).
- To assess the efficacy of a 48-week course of mavacamten compared to placebo on exercise capacity
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Participants must be at least 18 years old or local age of majority at the time of signing the informed consent
- •Female participants must adhere to highly effective contraceptive methods or have documented proof that they are not of childbearing potential
- •No additional contraceptive measures are required to be used for male participants
- •Diagnosis of HCM consistent with current American College of Cardiology Foundation/American Heart Association and European Society of Cardiology guidelines.
- •Peak LVOT pressure gradient < 30 mmHg at rest and < 50 mmHg with provocation (Valsalva maneuver and stress echocardiography)
- •CPET: Documented oxygen saturation at rest >90% at Screening. Able to perform an upright cardiopulmonary stress test (CPET) and has a respiratory exchange ratio (RER) ≥ 1.0 at Screening per central reading. If the RER is between 0.91 and 1.0, the participant may be enrolled if the central CPET laboratory determines that peak exercise has been achieved. Participants with subpeak performance may not be enrolled as described in the CPET Laboratory Manual.
- •New York Heart Association (NYHA) Class II or III
- •NT-proBNP≥200 pg/mL or BNP≥70 pg/mL
- •LVEF ≥60 % on screening echocardiography measured by Central Echocardiography Laboratory
- •KCCQ-23 CSS Score ≤ 85 at screening
排除标准
- •Medical Conditions - Known infiltrative or storage disorder causing cardiac hypertrophy that mimics nHCM such as amyloidosis, Fabry disease, or Noonan syndrome with LV hypertrophy Note: Investigators should not screen participants who have comprehensive Echo features suggestive of amyloidosis, including abnormal global longitudinal strain in the setting of an appropriate clinical picture which could include low voltage on ECG and severely elevated NT-proBNP or BNP - History of unexplained syncope within 6 months prior to screening - History of sustained ventricular tachyarrhythmia (> 30 seconds) within 6 months prior to Screening - Paroxysmal or persistent (non-permanent) AF detected at the time of screening. Permanent AF is allowed if the participant is anticoagulated and the investigator considers the heart rate adequately controlled - CV diseases or treatments that in the opinion of the investigator increase the unpredictability of or change the participants' clinical course. - Acute heart failure from 4 weeks prior to screening up to randomization - Coronary artery disease requiring intervention, including myocardial infarction (increase in cardiac enzymes in combination with symptoms of ischemia or new ischemic ECG changes), coronary artery bypass graft surgery, or other major CV surgery, stroke, or transient ischemic attack in the past 90 days - Women who are breastfeeding or pregnant. Prior/Concomitant Therapy - Any adjustments of beta-blockers, verapamil, or diltiazem within 2 weeks prior to Screening and up to the day of randomization - Concomitant use of strong inhibitors of cytochrome P450 (CYP) 2C19 Note: Use should be discontinued for a minimum of 5 elimination halflives prior to first dose of study intervention. Other Exclusion Criteria - Any other serious condition that in the opinion of the investigator could prevent participation in the study and follow-up, including active infection with COVID-19 from 4 weeks prior to screening up to randomization - Completed a study with an investigational device < 30 days prior to screening or an investigational drug < 5 half-lives prior to screening - Participants who have completed a study with mavacamten or aficamten -Enrolled in another study and receiving any investigational treatment (device or drug) other than the study intervention given in this study.
结局指标
主要结局
Change from baseline in KCCQ CSS at Week 48
Change from baseline in KCCQ CSS at Week 48
Change from baseline in pVO2 at Week 48
Change from baseline in pVO2 at Week 48
次要结局
- Change from baseline in VE/VCO2 slope to Week 48
- Proportion of participants with at least 1 class of NYHA improvement from baseline to Week 48
- (3.-4.) 3. Change from baseline in NT-pro BNP to Week 48 4. Change from baseline in cTn-T to Week 48
- (5.-6.) 5. Change from baseline in HCMSQ-SoB domain to Week 48 6. Time to First MACE-Plus events defined as any CV death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for heart failure, hospitalization for arrhythmias or appropriate ICD therapy
研究者
GSM-CT
Scientific
Myokardia Inc.
研究点 (78)
Loading locations...
相似试验
进行中（未招募）
3 期
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic CardiomyopathyCardiomyopathy, HypertrophicNCT06253221Bristol-Myers Squibb44
已完成
3 期
A Study of Mavacamten in Non-Obstructive Hypertrophic CardiomyopathyCardiomyopathy, HypertrophicNCT05582395Bristol-Myers Squibb580
进行中（未招募）
不适用
Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic CardiomyopathyNCT06947590Xu Liu78
招募中
3 期
A Study of Mavacamten in Adolescent Participants with Symptomatic Obstructive Hypertrophic Cardiomyopathy2023-505650-17-00Bristol-Myers Squibb Services Unlimited Company11
已完成
1 期
A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy ParticipantsHealthy ParticipantsNCT05658146Bristol-Myers Squibb95